Research analysts covering REGENEREX PHARMA.
Recent press releases and 8-K filings for RGPX.
Regenerex Pharma, Inc. enters into a supply and development agreement with Holista Colltech Ltd.
RGPX
New Projects/Investments
Product Launch
- Regenerex Pharma, Inc. (RGPX) has entered into a binding supply and development agreement with Holista Colltech Ltd. for the exclusive worldwide rights to market Holista's proprietary ovine collagen products for wound care applications.
- Under the agreement, Holista will exclusively manufacture and supply its ovine collagen for Regenerex's use in the development, clinical testing, and global distribution of advanced wound care products, with an initial focus on the United States.
- Regenerex is committed to minimum purchase commitments of USD50,000 in 2025, scaling to USD3 million in 2026, USD6 million in 2027, and USD9 million annually from 2028 onwards.
- Regenerex will also be responsible for conducting and funding clinical studies and regulatory approvals with the U.S. FDA and other relevant authorities.
Sep 3, 2025, 6:56 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more